Home / Market News / $ADNT
benzinga Corporate Catalyst Impact 55/100 ● negative

UBS Maintains Buy on Adient, Lowers Price Target to $23

Oct 7, 2026, 9:03 PM UTC · Primary ticker $ADNT

UBS analyst Joseph Spak reiterated a 'Buy' rating on Adient but reduced the price target from $29 to $23. This indicates a continued positive long-term outlook for the company, albeit with a revised, lower valuation expectation, which could lead to some short-term price pressure.

UBS analyst Joseph Spak maintained a 'Buy' rating on Adient, signaling continued confidence in the company's fundamentals. However, the price target was lowered from $29 to $23, suggesting a more conservative valuation or potential headwinds identified by the analyst. This adjustment could lead to some negative sentiment and short-term selling pressure on ADNT shares as investors digest the reduced price target. For traders, this presents a potential opportunity for short-term bearish plays or a long-term entry point if they believe the revised target still undervalues the company. The key risk is whether other analysts follow suit with similar price target reductions, creating further downward pressure.

$ADNT negative Price target lowered
Source: benzinga
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.